Kohjin Bio

Sakado, Japan Founded: 1981 • Age: 45 yrs
Tissue culture media provided for regenerative medicine and immunotherapy research.
Annual revenue $34.9M Latest available
Total funding - Funding intelligence
Employees 167 Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors 9 Brand Intelligence

About Kohjin Bio

Kohjin Bio is a company based in Sakado (Japan) founded in 1981. The company has 167 employees as of March 31, 2024. Kohjin Bio operates in a competitive market with competitors including Multus, Metatissue, Nu-Tek Biosciences, Sarvoshadhi Bio and metabolIQ, among others.

  • Headquarter Sakado, Japan
  • Employees 167 as on 31 Mar, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Legal Name Kohjin Bio Co.,Ltd.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
    $34.87 M (USD)
    9.14
    as on Mar 31, 2025
  • Net Profit
    $5.32 M (USD)
    106.44
    as on Mar 31, 2025
  • EBITDA
    $9.03 M (USD)
    50.83
    as on Mar 31, 2025
  • Latest Funding Round
  • Investors
  • Employee Count
    167

    as on Mar 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Kohjin Bio

Kohjin Bio is a publicly listed company on the TSE with ticker symbol 177A in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: TSE · Ticker: 177A · Sector: Health technology · Japan

Funding Insights of Kohjin Bio

Investments & Acquisitions by Kohjin Bio

Investments

Financial Statements - Kohjin Bio

Kohjin Bio Comparisons

+
Add Comparison
Available on Premium

Competitors of Kohjin Bio

Kohjin Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Multus, Metatissue, Nu-Tek Biosciences, Sarvoshadhi Bio and metabolIQ, among others.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Provider of lab-grown meat alternatives
domain founded_year HQ Location
Provider of human protein-based products for cell culture, tissue engineering, and disease modeling applications
domain founded_year HQ Location
Develops innovative animal-free peptones and cell culture media for pharmaceutical use.
domain founded_year HQ Location
Customized cell culture media for biotechnology are developed.
domain founded_year HQ Location
Developer of cell culture medium for pharmaceutical screening and personalized medicine

Latest news on Kohjin Bio

TABLE-Kohjin Bio -2025/26 group results
Reuters1 month ago
TABLE-Kohjin Bio - 9-MTH group results
Reuters4 months ago
TABLE-Kohjin Bio - 6-MTH group results
Reuters7 months ago

Frequently Asked Questions about Kohjin Bio

Kohjin Bio was founded in 1981.

Kohjin Bio is headquartered in Sakado, Japan. It is registered at Sakado, Saitama, Japan.

Takato Nakamura is the current CEO of Kohjin Bio.

As of Mar 31, 2024, the latest employee count at Kohjin Bio is 167.

Annual revenue of Kohjin Bio is $34.87M as on Mar 31, 2025.

Kohjin Bio was founded in 1981 in Sakado, Japan, as a provider of tissue culture media. Focus is placed on developing serum-free media for research applications in regenerative medicine and immunotherapy. Operations center on the production and supply of these specialized media to support scientific investigations in the biotechnology sector. The companys activities are based in Japan, serving global research needs.

Kohjin Bio's top competitors include Multus, Onkologic and Cellular Engineering Technologies.

Yes, Kohjin Bio is publicly traded on TSE under the ticker symbol 177A.

The ticker symbol of Kohjin Bio is 177A on TSE.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available